The MHRA has approved the product for three clinical settings, including identifying how far high-risk prostate cancer has ...
News-Medical.Net on MSN2d
World first as MHRA approves trofolastat for diagnostic imaging of prostate cancer in menThe Medicines and Healthcare products Regulatory Agency (MHRA) has approved trofolastat (RoTecPSMA), the first prostate-specific membrane antigen (PSMA)-targeting product authorised for use with ...
As with all products, the MHRA will keep its safety under close review. Prostate cancer is one of the most common cancers in ...
Medical Device Network on MSN5d
MHRA approves trofolastat for prostate cancer diagnostic imagingTrofolastat is a prostate-specific membrane antigen-targeting agent cleared for use with Technetium-99m for cancerous lesion ...
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved trofolastat (RoTecPSMA), the first prostate-specific membrane antigen (PSMA)-targeting product authorised for use with ...
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for trofolastat (RoTecPSMA), a prostate-specific membrane antigen (PSMA)-targeting agent for detecting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback